In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 191 to 200 of 303

TitleTypeExpected publication date
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Technology appraisal guidanceTBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Technology appraisal guidanceTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]Technology appraisal guidance
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594Technology appraisal guidanceTBC
Pegcetacoplan for treating geographic atrophy [ID4041]Technology appraisal guidanceTBC
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]Technology appraisal guidanceTBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473Technology appraisal guidanceTBC
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All